Meeting
2024 ASCO Genitourinary Cancers Symposium
Evaluation of provider preferences in first-line metastatic cisplatin-ineligible urothelial carcinoma in the setting of platinum shortages.
Authors
Michael Seth Weinfeld
University of Illinois Chicago, Chicago, IL
Michael Seth Weinfeld , Priyanka Vinod Chablani , Natalie Marie Reizine , Walter Michael Stadler , Karine Tawagi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 576)
DOI
10.1200/JCO.2024.42.4_suppl.576
Abstract #
576
Poster Bd #
F3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (la/mUC): Subgroup analyses of confirmed objective response rate (cORR) from EV-103 cohort K.
First Author: Peter H. O'Donnell
Poster
2021 ASCO Annual Meeting
Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
First Author: Terence W. Friedlander
Poster
2021 ASCO Annual Meeting
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.
First Author: Benjamin Miron
Poster
2019 ASCO Annual Meeting
EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
First Author: Christopher J. Hoimes